Array BioPharma

The Company’s wholly owned clinical stage drugs include Filanesib in Phase II clinical trials, is indicated for Kinesin spindle protein (KSP), inhibitor for MM; ARRY-797 in Phase II clinical trials, indicated for p38 inhibitor for Lamin A/C-related dilated cardiomyopathy (LMNA-DCM); ARRY-502 in Phase II clinical trials, indicated for CRTh2 antagonist for asthma, and ARRY-614 in Phase I clinical trials, is indicated for p38/Tie2 dual inhibitor for myelodysplastic syndromes (MDS). In addition, the Company has 11 ongoing partner-funded clinical programs, including two MEK inhibitors, which are both in Phase III clinical trials, binimetinib with Novartis and selumetinib with AstraZeneca.

Employee Rating

3.5More
TypeSubsidiary
Parent CompanyPfizer
HQBoulder, US
Founded1998
Websitearraybiopharma.com
Cybersecurity ratingAMore
Array BioPharma was founded in 1998 and is headquartered in Boulder, US

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Array BioPharma

Ron Squarer

Ron Squarer

CEO
Jason Haddock

Jason Haddock

CFO
Rogan P. Nunn

Rogan P. Nunn

Interim General Counsel
Kimberly Pope

Kimberly Pope

Senior Vice President, Human Resources
Andrew Robbins

Andrew Robbins

COO
Nicholas Saccomano

Nicholas Saccomano

Chief Scientific Officer
Show more

Array BioPharma Office Locations

Array BioPharma has offices in Boulder, Cambridge, Chicago, Detroit and in 5 other locations
Boulder, US (HQ)
3200 Walnut St
Cambridge, US
100 Cambridgepark Dr #505
Chicago, US
Chicago, IL, USA
Detroit, US
Detroit, MI, USA
Houston, US
Houston, TX, USA
Miami, US
Miami, FL, USA
Show all (9)

Array BioPharma Financials and Metrics

Summary Metrics

Founding Date

1998
Array BioPharma is a subsidiary of Pfizer

Array BioPharma Revenue

Embed Graph
View revenue for all periods
Array BioPharma's revenue was reported to be $173.77 m in FY, 2018
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

85.1m69.6m42.1m51.9m137.9m150.9m173.8m

Revenue growth, %

23%166%

Cost of goods sold

24.3m30.1m46.0m44.4m23.2m35.4m59.4m

Gross profit

60.9m39.5m(3.9m)7.5m114.7m115.5m114.4m
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

55.8m60.7m68.6m55.7m56.6m125.9m114.7m

Accounts Receivable

9.6m5.4m6.3m39.3m31.3m32.1m

Prepaid Expenses

3.9m3.5m5.2m6.4m4.6m7.0m

Inventories

6.1m
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

72.4m60.4m63.0m49.1m59.6m44.0m65.0m47.2m52.2m46.8m68.1m141.5m56.4m57.3m62.5m65.8m62.8m83.7m295.4m65.1m73.9m130.5m147.1m96.6m

Accounts Receivable

1.0m5.7m4.4m6.0m4.9m2.1m13.5m64.8m62.9m33.9m43.1m32.5m26.6m30.0m44.2m44.4m22.2m31.7m

Prepaid Expenses

4.8m4.2m4.7m3.6m5.1m7.6m10.0m3.1m3.7m6.1m4.3m4.4m6.8m7.2m6.7m7.4m6.8m7.7m3.7m4.6m5.2m17.4m31.5m34.8m

Inventories

4.4m
USDQ1, 2012

Financial Leverage

-0.7 x
Show all financial metrics

Array BioPharma Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Array BioPharma Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Array BioPharma Online and Social Media Presence

Embed Graph

Array BioPharma Company Culture

  • CEO Rating

    A+

    100/100

  • Compensation

    A+

    100/100

Learn more on Comparably

Array BioPharma News and Updates

Array BioPharma Inc., a Subsidiary of Pfizer Inc., Announces Effective Date of Make-Whole Fundamental Change and Fundamental Change Company Notice Relating to its 2.625% Convertible Senior Notes due 2024

BOULDER, Colo., July 30, 2019 /PRNewswire/ -- Array BioPharma Inc. ("Array") today announced that, in connection with the closing of the merger (the "Merger") contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 14, 2019, by and among Array, Pfizer...

Array BioPharma Announces Interim Analysis Results from the BEACON CRC Trial of BRAFTOVI + MEKTOVI + Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer at the ESMO 21st World Congress on Gastrointestinal Cancer

BOULDER, Colo., July 6, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced the presentation of results from the Phase 3 BEACON CRC trial evaluating the combination of BRAFTOVI® (encorafenib), a BRAF inhibitor, MEKTOVI® (binimetinib), a MEK inhibitor, and ERBITUX®...

Thinking about trading options or stock in Array Biopharma, JPMorgan Chase, Coca-Cola, Match Group, or Netflix?

NEW YORK, June 20, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ARRY, JPM, KO, MTCH, and NFLX. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...

3 biotechs that investors should buy next after Pfizer's $11 billion deal for cancer drugmaker Array BioPharma

US drug giant Pfizer just announced that it is acquiring biotech Array BioPharma for $11.4 billion.  This latest deal points to a trend of big companies snapping up cancer-focused biotechs, with Merck buying the cancer biotech Tilos Therapeutics for up to $773 million last week. Investors should c…

Thinking about buying stock in Aurora Cannabis, Array Biopharma, Beyond Meat, Dare Bioscience, or Uniqure?

NEW YORK, June 17, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, ARRY, BYND, DARE, and QURE. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. ...
Show more

Array BioPharma Blogs

Array BioPharma to Present Interim Analysis Results from Phase 3 BEACON CRC Trial of BRAFTOVI + MEKTOVI + Cetuximab for the Treatment of BRAFV600E- Mutant Metastatic Colorectal Cancer at the ESMO 21st World Congress on Gastrointestinal Cancer

BOULDER, Colo. , June 25, 2019 /PRNewswire/ --   Array BioPharma Inc. (Nasdaq: ARRY) announced that it will present updated data from the combination of BRAFTOVI ® (encorafenib), a BRAF inhibitor, MEKTOVI ®  (binimetinib), a MEK inhibitor, and ERBITUX ®  (cetuximab), an anti-EGFR antibody (BRAFTOVI

Array BioPharma to Present at the Jefferies 2019 Global Healthcare Conference

BOULDER, Colo. , May 29, 2019 /PRNewswire/ --  Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will speak at the Jefferies 2019 Global Healthcare Conference in New York City . The public is welcome to participate in the conference through a

Array BioPharma Announces BRAFTOVI + MEKTOVI + Cetuximab Meet Primary Endpoints of ORR and OS in Phase 3 BEACON CRC Trial Interim Analysis for the Treatment of BRAF(V600E)-mutant Metastatic Colorectal Cancer

- BRAFTOVI combinations showed statistically significant improvement in ORR and OS versus control - - BRAFTOVI + MEKTOVI + cetuximab reduced the risk of death by 48% versus control - - Potential to be the first chemotherapy-free, targeted regimen for metastatic CRC patients - - Array intends to

BRAFTOVI® (encorafenib) in Combination with MEKTOVI® (binimetinib) and ERBITUX® (cetuximab) or panitumumab Recommended by the National Comprehensive Cancer Network® (NCCN) Guidelines as a Treatment Option for Patients with Advanced BRAF-mutant Colorectal

BOULDER, Colo. , March 18, 2019 /PRNewswire/ --  Array BioPharma Inc. (NASDAQ: ARRY) today announced that the National Comprehensive Cancer Network ® (NCCN ® ) has updated their Clinical Practice Guidelines in Oncology for Colon and Rectal Cancer to include BRAFTOVI ® in combination with MEKTOVI ®

Array BioPharma to Present at the 39th Annual Cowen Health Care Conference

BOULDER, Colo. , March 5, 2019 /PRNewswire/ --  Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will speak at the 39 th Annual Cowen Health Care Conference in Boston . The public is welcome to participate in the conference through a webcast on the

Array BioPharma to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference

BOULDER, Colo. , Feb. 21, 2019 /PRNewswire/ --  Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will speak at the SVB Leerink Partners 8 th Annual Global Healthcare Conference in New York.  The public is welcome to participate in the conference
Show more

Array BioPharma Frequently Asked Questions

  • When was Array BioPharma founded?

    Array BioPharma was founded in 1998.

  • Who are Array BioPharma key executives?

    Array BioPharma's key executives are Ron Squarer, Jason Haddock and Rogan P. Nunn.

  • How many employees does Array BioPharma have?

    Array BioPharma has 298 employees.

  • What is Array BioPharma revenue?

    Latest Array BioPharma annual revenue is $173.8 m.

  • What is Array BioPharma revenue per employee?

    Latest Array BioPharma revenue per employee is $583.1 k.

  • Who are Array BioPharma competitors?

    Competitors of Array BioPharma include Recro Gainesville, BTG and Zogenix.

  • Where is Array BioPharma headquarters?

    Array BioPharma headquarters is located at 3200 Walnut St, Boulder.

  • Where are Array BioPharma offices?

    Array BioPharma has offices in Boulder, Cambridge, Chicago, Detroit and in 5 other locations.

  • How many offices does Array BioPharma have?

    Array BioPharma has 9 offices.